This statistic depicts the percentage of U.S. adults who had ever been told by a health professional that they had high blood cholesterol as of 2015, by state. According to the data, among respondents living in Arkansas, 35.6 percent had been told by a health care professional that they had high blood cholesterol.

In 2023, it was estimated that around 48 percent of those aged 65 years and older in the United States had been diagnosed with high cholesterol. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had high cholesterol from 2019 to 2023.

This web map is part of the Centers for Disease Control and Prevention (CDC) PLACES. It provides model-based estimates of high cholesterol prevalence among adults aged 18 years and old at county, place, census tract, and ZCTA levels in the United States. PLACES is an expansion of the original 500 Cities Project and a collaboration between the CDC, the Robert Wood Johnson Foundation, and the CDC Foundation. Data sources used to generate these estimates include the Behavioral Risk Factor Surveillance System (BRFSS), Census 2020 population counts or Census annual county-level population estimates, and the American Community Survey (ACS) estimates. For detailed methodology see www.cdc.gov/places. For questions or feedback send an email to places@cdc.gov.Measure name used for high cholesterol is HIGHCHOL.

In the period August 2021 to August 2023, a total of **** percent of adults in the United States had high cholesterol, a decrease from **** percent in 1999-2000. This statistic shows the trends in high total cholesterol among adults aged 20 years and above in the U.S. from 1999 to 2023.

Data on cholesterol in adults age 20 and older in the United States, by selected characteristics. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Data on cholesterol in adults age 20 and older in the United States, by selected characteristics. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

This data represents the age-adjusted prevalence of high total cholesterol, hypertension, and obesity among US adults aged 20 and over between 1999-2000 to 2017-2018. Notes: All estimates are age adjusted by the direct method to the U.S. Census 2000 population using age groups 20–39, 40–59, and 60 and over. Definitions Hypertension: Systolic blood pressure greater than or equal to 130 mmHg or diastolic blood pressure greater than or equal to 80 mmHg, or currently taking medication to lower high blood pressure High total cholesterol: Serum total cholesterol greater than or equal to 240 mg/dL. Obesity: Body mass index (BMI, weight in kilograms divided by height in meters squared) greater than or equal to 30. Data Source and Methods Data from the National Health and Nutrition Examination Surveys (NHANES) for the years 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were used for these analyses. NHANES is a cross-sectional survey designed to monitor the health and nutritional status of the civilian noninstitutionalized U.S. population. The survey consists of interviews conducted in participants’ homes and standardized physical examinations, including a blood draw, conducted in mobile examination centers.

DQS Cholesterol in adults age 20 and older, by selected characteristics: United States

  Description

Data on cholesterol in adults age 20 and older in the United States, by selected characteristics. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from:… See the full description on the dataset page: https://huggingface.co/datasets/HHS-Official/dqs-cholesterol-in-adults-age-20-and-older-by-sele.

In 2023, around 24 percent of men and 23 percent of women in the United States had high cholesterol in the United States. This statistic shows the prevalence of high total cholesterol among adults in the U.S. from 2019-2023, by gender

Ratio: Percentage of adults who have had their blood colesteral checked (within 5 years).

Definition: Proportion of adults aged 18 and older who have had their blood cholesterol checked by a health professional within the past five years.

Data Source: State of New Jersey Department of Health, Center for Health Statistics and Informatics, New Jersey Behavioral Risk Factor Survey

The NHANES II Serum Cholesterol data file contains two parts of the extensive data available from NHANES II: demographic information obtained during the household interview on all examined participants, and laboratory results (for a subset of those examined) on one of the serum lipids relevant to cardiovascular disease (cholesterol, triglycerides, and high density lipoproteins). The demographic data include information on the type of residence and housing, composition of the household, vehicles, languages spoken, income sources and amounts, food stamps and commodity foods, employment, age, race and national ancestry, sex, education, marital status, veteran status, and region of country. The serum lipid data in this file are the Abell-Kendall serum cholesterol values, obtained from laboratory analyses of blood serum samples from fasting and non-fasting individuals.

Diabetes, hypertension, and hypercholesterolemia are three of the major risk factors for the development of cardiovascular disease (CVD), a leading cause of death in the United States. The burden of these disorders is not uniform across the country primarily due to socioeconomic status, cultural practices, and lifestyle. To evaluate the effect of these disparities, this study compared the prevalence of the 3 conditions in a subpopulation in the US with that of the general population. The Old Order Amish (OOA) community located in rural Pennsylvania is characterized by distinctive sociocultural practices that include a very cohesive social structure and limited use of modern technologies and medication. A total of 5377 OOA individuals took part in a community-wide survey which included a physical exam and fasting blood draw. The prevalence of the 3 risk factors in the Amish was then compared to the European Caucasian subsample of the 2013–2014 US National Health and Nutrition Examination Survey (NHANES). This dataset includes demographics, physical examination values, medication history, clinical measures associated blood pressure, cholesterol, and glucose, and statistical assessment and comparison data.

In 2023, around a quarter of adults who were non-Hispanic white had high cholesterol in the United States. This statistic shows the prevalence of high total cholesterol among adults in the U.S. from 2019 to 2023, by race/ethnicity.

This dataset tracks the updates made on the dataset "DQS Cholesterol in adults age 20 and older, by selected characteristics: United States" as a repository for previous versions of the data and metadata.

The global cholesterol and lipid test market size reached US$ 2.7 billion in 2023 and is anticipated to expand at a 7.6% CAGR during the forecast period. Total market valuation is predicted to increase from US$ 3.0 billion in 2024 to US$ 6.2 billion by 2034.

Attributes	Key Insights
Cholesterol and Lipid Test Market Value in 2023	US$ 2.7 billion
Estimated Cholesterol and Lipid Test Market Value (2024E)	US$ 3.0 billion
Projected Cholesterol and Lipid Test Market Value (2034F)	US$ 6.2 billion
Expected Cholesterol and Lipid Test Market CAGR of (2024 to 2034)	7.6%
Market Share of Top 5 Countries	51.9%

Historical Performance Vs. Global Cholesterol and Lipid Test Market Forecast

Historical CAGR (2019 to 2023)	7.6%
Forecast CAGR (2024 to 2034)	7.6%

Country Wise Insights

Countries	CAGR (2024 to 2034)
United States	6.4%
China	6.8%
United Kingdom	7.8%
Japan	6.5%
Germany	7.6%
India	8.4%

Category-wise Insights

Product	Value CAGR
Test Strip Kits	8.3%
Analyzer Kits	7.4%

Test Type	Value CAGR
Total Cholesterol Test	6.0%
HDL Cholesterol Test	7.1%
LDL Cholesterol Test	7.9%
Triglycerides/VLDL Cholesterol Test	8.7%
Others	9.0%

Application	Value CAGR
Hyperlipidemia	6.9%
Hypertriglyceridemia	8.0%
Hyperlipoproteinemia	8.5%
Tangier Disease	6.4%
Familial Hypercholesterolemia	7.5%
Others	8.8%

End-user	Value CAGR
Clinics	6.8%
Hospitals	7.5%
Ambulatory Surgical Centers	8.3%
Homecare Settings	7.8%
Diagnostic Centers	7.2%

This dataset contains model-based place (incorporated and census-designated places) estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

This dataset contains model-based place (incorporated and census-designated places) level estimates for the PLACES 2022 release. PLACES covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 13 for health outcomes, 9 for preventive services use, 4 for chronic disease-related health risk behaviors, and 3 for health status. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2020 or 2019 data, Census Bureau 2010 population data, and American Community Survey 2015–2019 estimates. The 2022 release uses 2020 BRFSS data for 25 measures and 2019 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

This dataset contains model-based county estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. This dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2022 county population estimate data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

According to Cognitive Market Research, The Global Cholesterol market size is USD 4.5 billion in 2023 and will grow at a compound annual growth rate (CAGR) of 7.80% from 2023 to 2030.

The global cholesterol market will expand at a significant 7.80% CAGR between 2023 and 2030.
Growing elderly populations, expanding awareness of routine cholesterol monitoring, and rising incidence of elevated cholesterol levels are important market growth drivers.
Demand for high-density lipoprotein remains higher in the cholesterol market.
The Animal-derived category held the highest source in cholesterol market share in 2023.
In 2023, North America held the biggest market share for cholesterol. This is due to increased obesity and heart disease in the United States, rising public awareness and organizational and governmental activities, and a growing desire for preventative treatment.

Surge in Obesity in the Populace Provides Viable Market Output

A rise in the prevalence of obesity has resulted in a rise in the demand for goods and services that control cholesterol levels and general cardiovascular health. This presents various opportunities for the cholesterol market to provide viable solutions that cater to the needs of the growing population concerned about their health. The market can offer a range of cholesterol-lowering supplements and nutraceuticals formulated with ingredients like plant sterols, omega-3 fatty acids, soluble fiber, and antioxidants. These products can help individuals manage their cholesterol levels while complementing their diets.

As an illustration, the WHO's 2021 statistics estimate that 38.2 million children under 5 were overweight or obese that year. Children eat more processed meals and junk food, which reduces the body's supply of vitamins and increases their chance of high cholesterol. As a result, there is a greater demand for frequent cholesterol screening, which is expected to fuel market expansion over the coming years.

(Source:www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

Market Dynamics of Cholesterol

Low Accuracy in Cholesterol Test Kits to Hinder Market Growth

The accuracy of cholesterol test kits is crucial for individual health management and the overall credibility of the cholesterol market. If test kits provide low accuracy, it can lead to misinformation, ineffective management strategies, and a lack of trust among consumers. This can certainly hamper the growth and reputation of the cholesterol market. Inaccurate test results could lead individuals to make incorrect health decisions. They might unnecessarily modify their diet, medication, or lifestyle based on incorrect information, potentially leading to negative health outcomes.

Impact of COVID-19 on the Market for Cholesterol

The COVID-19 pandemic had a detrimental effect on the cholesterol test business since most blood test labs encountered various issues, and most of them were more severely impacted by the pandemic's second wave. Due to mail delays, unreliability, and airline cancellation, samples arriving at test centers and the availability of laboratory equipment and reagents were all delayed. The availability of the laboratory staff was periodically restricted due to infection, quarantine, or relocation within the healthcare institution. Introduction of Cholesterol

Due to the large number of customers concerned about their health, the pharmaceutical sector is growing and innovating, which opens up opportunities for the cholesterol test market. The expansion of the global market for cholesterol is anticipated to be aided by the availability of enhanced healthcare infrastructure, an increase in unmet healthcare demands, a rise in the incidence of cardiovascular disease, and a spike in demand for cholesterol test kits. The need for improved healthcare services, significant government expenditures to improve the healthcare infrastructure, and the expansion of the medical tourism industry in developing economies are all factors that have contributed to the massive growth of the healthcare sector in emerging economies.

For instance, in an article published by Medical News Today in August 2023, the body naturally manufactures cholesterol, but humans also ingest it through meals, including meat, dairy, and poultry. Some people have a history of high cholesterol in their families, and genetic factors could be involved....

This dataset contains model-based census tract-level estimates for the PLACES project 2020 release. The PLACES project is the expansion of the original 500 Cities project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code tabulation Areas (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 27 measures: 5 chronic disease-related unhealthy behaviors, 13 health outcomes, and 9 on use of preventive services. These estimates can be used to identify emerging health problems and to inform development and implementation of effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2018 or 2017 data, Census Bureau 2010 population data, and American Community Survey (ACS) 2014-2018 or 2013-2017 estimates. The 2020 release uses 2018 BRFSS data for 23 measures and 2017 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening). Four measures are based on the 2017 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at www.cdc.gov/places.